Authors suggest limiting duration of oral corticosteroid treatment to 90 days or less to reduce risk of adverse effects<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, July 24, 2024 (HealthDay News) — Use of oral corticosteroids for >90 days during one year is associated with a slightly increased risk of adverse events (AEs), according to a study published online July 19 in\u00a0JAMA Network Open<\/em>.<\/p>\n Yong Hyun Jang, M.D., Ph.D., from Kyungpook National University in Daegu, South Korea, and colleagues examined the association between long-term exposure to oral corticosteroids and occurrence of 11 AEs among adult patients with atopic dermatitis. Analysis included 164,809 cases and 328,303 controls.<\/p>\n The researchers found that 3.4 percent of cases and 3.2 percent of controls were exposed to oral corticosteroids for >30 days, while 0.4 percent in both groups were exposed to oral corticosteroids for >90 days. There was no increased risk of AEs with use of oral corticosteroids for >30 days (adjusted odds ratio, 1.00; 95 percent confidence interval, 0.97 to 1.04). However, the risk was higher with use of oral corticosteroids for >90 days (adjusted odds ratio, 1.11; 95 percent confidence interval, 1.01 to 1.23). For each cumulative or consecutive year of ever long-term use, there was a small elevation of risk for experiencing an AE.<\/p>\n “This study suggests that for patients with exacerbations of atopic dermatitis, limiting the duration of oral corticosteroid treatment to 90 days or less may limit adverse effects,” the authors write.<\/p>\n Several authors disclosed ties to the pharmaceutical industry.<\/p>\n